Display options
Cite
Goel S, Marwah A, Kaushik S, et al. Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus. J Clin Exp Dent. 2015;7(4):e477-82doi: 10.4317/jced.52376.
Goel, S., Marwah, A., Kaushik, S., Garg, V. K., & Gupta, S. (2015). Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus. Journal of clinical and experimental dentistry, 7(4), e477-82. https://doi.org/10.4317/jced.52376
Goel, Sinny, et al. "Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus." Journal of clinical and experimental dentistry vol. 7,4 (2015): e477-82. doi: https://doi.org/10.4317/jced.52376
Goel S, Marwah A, Kaushik S, Garg VK, Gupta S. Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus. J Clin Exp Dent. 2015 Oct 01;7(4):e477-82. doi: 10.4317/jced.52376. eCollection 2015 Oct. PMID: 26535093; PMCID: PMC4628801.
Copy Download .nbib Format: NLM
Share it on

J Clin Exp Dent. 2015 Oct 01;7(4):e477-82. doi: 10.4317/jced.52376. eCollection 2015 Oct.

Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus.

Journal of clinical and experimental dentistry

Sinny Goel, Akanksha Marwah, Smita Kaushik, Vijay K Garg, Sunita Gupta

Affiliations

  1. MDS, Postgraduate student, Dept. of Oral Medicine and Radiology, Maulana Azad Institute of Dental Sciences, Delhi.
  2. MSc. Research associate, Dept. of Oral Medicine and Radiology, Maulana Azad Institute of Dental Sciences, Delhi.
  3. MD, Professor, Dept. of Biochemistry, Maulana Azad Medical College, Delhi.
  4. MD, MNAMS, Director Professor & Head, Department of Dermatology & STD, Maulana Azad Medical College and Associated Lok Nayak Hospital.
  5. MDS, MBA (HCA), FICD (USA), Professor and Head, Dept. of Oral Medicine and Radiology, Maulana Azad Institute of Dental Sciences, Delhi.

PMID: 26535093 PMCID: PMC4628801 DOI: 10.4317/jced.52376

Abstract

BACKGROUND: Oral lichen planus (OLP) is a T cell mediated immune response. T cells locally present in the involved tissues release cytokines like interleukin-6 (IL-6), which contributes to pathogenesis of OLP. Also IL-6 has been associated with multidrug resistance protein (MRP) expression by keratinocytes. Correspondingly, upregulation of MRP was found in OLP. We conducted this study to evaluate the effects of various drugs on serum IL-6 in OLP; and correlation of these effects with the nature of clinical response and resistance pattern seen in OLP lesions with various therapeutic modalities. Thus we evaluated the role of serum IL-6 in deciding therapy for multidrug resistant OLP.

MATERIAL AND METHODS: Serum IL-6 was evaluated in 42 erosive OLP (EOLP) patients and 10 normal mucosa and 10 oral squamous cell carcinoma cases using ELISA technique. OLP patients were randomly divided into 3 groups of 14 patients each and were subjected to Pimecrolimus local application, oral Mycophenolate Mofetil (MMF) and Methotrexate (MTX) alongwith Pimecrolimus local application. IL-6 levels were evaluated before and after treatment.

RESULTS: Serum IL-6 levels were raised above 3pg/ml in 26.19% erosive OLP (EOLP) cases (mean- 3.72±8.14). EOLP (5%) cases with IL-6 levels above 5pg/ml were resistant in MTX group. However significant decrease in serum IL-6 corresponding with the clinical resolution was seen in MMF group.

CONCLUSIONS: Significantly raised IL-6 levels in EOLP reflect the chronic inflammatory nature of the disease. As serum IL-6 levels significantly decreased in MMF group, correspondingly no resistance to treatment was noted. However with MTX there was no significant decrease in IL-6 and resistance to treatment was noted in some, especially plaque type lesions. Thus IL-6 can be a possible biomarker in deciding the best possible therapy for treatment resistant OLP.

KEY WORDS: Lichen planus, biological markers, cytokines, enzyme-linked immunosorbent assay, immunosuppressive agents.

References

  1. J Oral Pathol Med. 2012 Apr;41(4):315-21 - PubMed
  2. Cancer Treat Rev. 2012 Nov;38(7):904-10 - PubMed
  3. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Dec;98(6):673-8 - PubMed
  4. Acta Derm Venereol. 2002;82(1):63-4 - PubMed
  5. Cytokine. 2008 Feb;41(2):144-9 - PubMed
  6. Arch Dis Child. 2003 Nov;88(11):969-73 - PubMed
  7. Pharmacol Ther. 2014 Feb;141(2):125-39 - PubMed
  8. Arch Dermatol Res. 1999 Sep;291(9):485-90 - PubMed
  9. J Invest Dermatol. 2005 Jan;124(1):28-37 - PubMed
  10. Br J Dermatol. 2008 Sep;159(4):936-41 - PubMed
  11. Arch Dermatol. 2007 Apr;143(4):511-5 - PubMed
  12. J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1061-7 - PubMed
  13. Br J Dermatol. 2012 Jul;167(1):36-43 - PubMed
  14. J Oral Pathol Med. 1991 Jul;20(6):275-9 - PubMed
  15. J Am Acad Dermatol. 2007 Nov;57(5):806-13 - PubMed
  16. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e410-3 - PubMed
  17. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):164-78 - PubMed
  18. J Oral Pathol. 1987 Aug;16(7):356-61 - PubMed
  19. J Invest Dermatol. 2004 Jan;122(1):87-94 - PubMed
  20. Clin Pharmacol Ther. 2010 Apr;87(4):483-7 - PubMed
  21. J Eur Acad Dermatol Venereol. 2007 Feb;21(2):259-60 - PubMed
  22. J Am Acad Dermatol. 2003 Dec;49(6):1063-6 - PubMed
  23. Oral Surg Oral Med Oral Pathol. 1991 Dec;72 (6):665-70 - PubMed
  24. Inflamm Bowel Dis. 2011 Jun;17(6):1438 - PubMed
  25. J Periodontol. 2005 Apr;76(4):627-35 - PubMed
  26. Immunopharmacology. 1993 Jul-Aug;26(1):11-20 - PubMed
  27. J Oral Pathol Med. 2002 Apr;31(4):196-203 - PubMed
  28. Oral Dis. 2012 Apr;18(3):236-43 - PubMed
  29. J Oral Pathol Med. 1994 Jan;23(1):28-35 - PubMed

Publication Types